From: Impaired cardiac and peripheral hemodynamic responses to inhaled β2-agonist in cystic fibrosis
Control | Cystic fibrosis | P | |
---|---|---|---|
n | 30 | 18 | |
Age, years | 27±2 | 22±2 | 0.04 |
Gender, male/female | 18/12 | 13/5 | 0.54 |
Height, cm | 172±2 | 167±2 | 0.07 |
Weight, kg | 71±2 | 64±4 | 0.09 |
Body mass index, kg/m2 | 24±1 | 23±1 | 0.32 |
Body surface area, m2 | 1.8±0.0 | 1.7±0.1 | 0.04 |
Blood urea nitrogen, mg/dL | 14.4±0.8 | 15.1±1.1 | 0.61 |
Serum creatinine, mg/dL | 1.01±0.03 | 0.92±0.04 | 0.18 |
Serum sodium, mEq/L | 139±0 | 138±1 | 0.11 |
Serum chloride, mEq/L | 105±0 | 103±1 | 0.20 |
Albuterol dose (body weight standardized) | |||
Mean, μg/kg | 36±1.2 | 41.0±2.0 | 0.04 |
Functional capacity and physical activity | |||
Peak oxygen uptake, mL/kg/min | 35.1±2.1 | 23.7±2.2 | <0.01 |
Peak oxygen uptake, % of predicted | 97±6 | 55±5 | <0.01 |
Exercise hours/week (self report) | 7±1 | 9±3 | 0.23 |
Pulmonary function test parameters | |||
Forced vital capacity (L) | 4.6±0.2 | 3.7±0.3 | 0.01 |
Forced vital capacity (%predicted) | 97.3±2.8 | 83.2±4.7 | 0.02 |
FEV1 (L) | 3.7±0.1 | 2.7±0.3 | <0.01 |
FEV1 (%predicted) | 94.7±2.6 | 73.8±6.1 | <0.01 |
FEV1/FVC | 0.8±0.0 | 0.7±0.0 | <0.01 |
FEF25-75 (L/sec) | 3.7±0.1 | 2.2±0.4 | <0.01 |
FEF25-75 (%predicted) | 89.6±4.0 | 54.2±8 | <0.01 |
Medications (n) | |||
Bronchodilators (e.g. ProAir) | 0 | 13 | |
Taking >1 bronchodilator | 0 | 4 | |
Antibiotics (oral or inhaled) | 0 | 14 | |
Inhaled (e.g. Tobramycin) | 0 | 9 |